Triptolide-Nanoliposome-Aprpg, A Novel Sustained-Release Drug Delivery System Targeting Vascular Endothelial Cells, Enhances The Inhibitory Effects Of Triptolide On Laser-Induced Choroidal Neovascularization

Purpose: To investigate whether triptolide-nanoliposome-APRPG (TP-nanolip-APRPG), a novel sustained-release nano-drug delivery system that targets vascular endothelial cells, could enhance the inhibition of triptolide (TP) on laser-induced choroidal neovascularization (CNV).Methods: TP was encapsulated with or without APRPG (Ala-Pro-Arg-Pro-Gly) peptide-modified nanoliposomes. CNV was induced by laser photocoagulation in C57BL/6J mice. One microliter of 10 mu g free TP monomer, TPnanolip containing 10 mu g TP, TP-nanolip-APRPG containing 10 mu g TP, or an identical volume of PBS was intravitreally injected in mice immediately after laser photocoagulation. Seven days after laser photocoagulation, CNV volumes were calculated in each group. Infiltration of M2 macrophages as well as protein levels of vascular endothelial growth factor (VEGF) and inflammatory factors including ICAM-1 and MCP-1 in the RPE-choroid complex were determined. In vitro assays for cell proliferation, migration, and tube formation were also performed.Results: TP-nanolip-APRPG was successfully synthesized and exhibited good TP delivery and enhanced the cellular uptake of TP in vitro. In vitro studies showed that TP-nanolip-APRPG was a better inhibitor of cell proliferation (31.34 +/- 3.89 % vs 41.25 +/- 4.67 % vs 53.55 +/- 5.76 %), migration (62.60 +/- 8.88 vs 104.60 +/- 13.32 vs 147.00 +/- 13.15), and tube formation (681.26 +/- 108.15 vs 926.75 +/- 54.01 vs 1189.84 +/- 157.14) than TP-nanolip or free TP (all P < 0.05). Intravitreal injections of free TP (77588.10 +/- 7719.28 mu m(3)), TP-nanolip (64628.23 +/- 5857.96 mu m(3)), and TP-nanolip-APRPG (50880.34 +/- 6606.56 mu m(3)) inhibited the development of CNV compared with the PBS control group (120338.07 +/- 17428.90 mu m(3)) (P < 0.01, n=6). TP-nanolip-APRPG and TP-nanolip significantly down-regulated the protein levels of VEGF (152.76 +/- 19.55 vs 182.24 +/- 19.98 vs 208.55 +/- 21.93 pg/mg total protein) and inflammatory factors including ICAM-1 (61.69 +/- 3.49 vs 72.04 +/- 3.49 vs 81.92 +/- 4.09 ng/mg total protein) and MCP-1 (40.14 +/- 3.50 vs 50.75 +/- 4.18 vs 60.27 +/- 5.23 pg/mg total protein) compared with the free TP monomer group (all P < 0.05, n=8), which paralleled the decreased infiltration of M2 macrophages in the CNV lesions. Moreover, no influence on retinal morphology and function was observed before or after treatment in each group (P > 0.05, n=6).Conclusions: TP-nanolip-APRPG, a novel sustained-release drug delivery system targeting endothelial cells of CNV lesions, could enhance TP inhibition of the development of CNV without toxicity in the retina, suggesting therapeutic potential for CNV-related diseases in future clinical practice.